Safety of a refrigerator-stable varicella vaccine (VARIVAX®) in healthy 12-to 15-month-old children - A randomized, double-blind, cross-over study

Human Vaccines

Volumn 5, Issue 7, 2009, Pages 455-460

  Ferrera, Giuseppe ^a   Gajdos, Vincent ^b,c,d   Thomas, Stéphane ^e   Tran, Clément ^e   Figuet, Anne ^e  

^a Dipartimento di Prevenzione AUSL n7   (Italy)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d INSERM   (France)

^e SANOFI PASTEUR   (France)

Author keywords

MMR; Post licensure; Randomized cross over trial; Refrigerated vaccine; Safety; Tolerability; Vaccination; Varicella

Indexed keywords

CHICKENPOX VACCINE; IMMUNOGLOBULIN; MEASLES MUMPS RUBELLA VACCINE;

ARTICLE; BODY TEMPERATURE MEASUREMENT; CHICKENPOX; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROENTERITIS; GROUPS BY AGE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFANT; INJECTION SITE BLEEDING; INJECTION SITE DERMATITIS; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE VESICLE; LARYNX SPASM; LUNG DISEASE; MALE; MULTICENTER STUDY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VACCINATION;

EID: 70349528117     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.8269     Document Type: Article

References (30)

1. Heininger U, Seward JF. Varicella. Lancet 2006; 368:1365-76.
2. Galil K, Brown C, Lin F, Seward J. Hospitalizations for varicella in the United States, 1988 to 1999. Pediatr Infect Dis J 2002; 21:931-5.
3. Rawson H, Crampin A, Noah N. Deaths from chickenpox in England and Wales 1995-7: analysis of routine mortality data. BMJ 2001; 323:1091-3.
4. Gershon AA. Takahashi M, Seward J. Varicella vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. 4th edn. Philadelphia, PA: WB Saunders 2004; 783-823.
5. Schmader KE, Dworkin RH. Natural history and treatment of herpes zoster. J Pain 2008; 9:3-9.
6. Sengupta N, Booy R, Schmitt HJ, Peltola H, Van-Damme P, Schumacher RF, et al. Varicella vaccination in Europe: are we ready for a universal childhood programme? Eur J Pediatr 2008; 167:47-55.
7. Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1996; 45:1-25.
8. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005; 191:2002-7.
9. Davis MM, Patel MS, Gebremariam A. Decline in varicella-related hospitalisations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics 2004; 114:786-92.
10. Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A. Impact of varicella vaccination on health care utilization. JAMA 2005; 294:797-802.
11. Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 2005; 352:450-8.
12. Weibel RE, Kuter BJ, Neff BJ, Rothenberger CA, Fitzgerald AJ, Connor KA, et al. Live Oka/Merck varicella vaccine in healthy children. Further clinical and laboratory assessment. JAMA 1985; 254:2435-9.
13. Vessey SJR, Chan CY, Kuter BJ, Kaplan KM, Waters M, Kutzler DP, et al. Childhood vaccination against varicella: persistence of antibody, duration of protection and vaccine efficacy. J Pediatr 2001; 139:297-304.
14. Li S, Chan I, Matthews H, Heyse JF, Chan CY, Kuter BJ, et al. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J 2002; 21:337-42.
15. Kuter B, Matthews H, Shinefield H, Black S, Dennehy P, Watson B, et al, and the Study Group for VARIVAX. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 2004; 23:132-7.
16. Clements DA, Zaref JI, Bland CL, Walter EB, Coplan PM. Partial up-take of varicella vaccine and the epidemiological effect of varicella disease in 11 day-care centers in North Carolina. Arch Pediatr Adolesc Med 2001; 155:455-61.
17. Vázquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001; 344:955-60.
18. Jones T. Varivax (Merck & Co.,). Curr Opin Invest Drugs 2002; 3:54-7.
19. Strebel PM, Papania MJ, Halsey NA. Measles vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines, 4th edn. Philadelphia, PA: WB Saunders 2004; 389-440.
20. Jones B, Kenward MG. Design and Analysis of Cross-Over Trials. New York: Chapman & Hall 1989.
21. M-M-RvaxPro® Product information. http://www.emea.europa.eu /humandocs/Humans/EPAR/mmrvaxpro/mmrvaxpro.htm Accessed 2008.
22. Henderson FW, Reisinger K, Malacaman EA, Levin MJ, Bromberg K, Dennehy P, et al. Process upgrade varicella vaccine (PUVV) in concomitant use with MMR II in healthy children. 22nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Tampere, Finland 2004.
23. Mendez R, Henderson F, Reisinger K, Malacaman E, Harmon A, Waters M, et al. Immunogenicity and safety of process upgrade varicella vaccine (PUVV) with new stabilizer as compared to PUVV with current stabilizer when administered concomitantly with MMR™ II in healthy children. 22nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) Tampere, Finland 2004.
24. Gershon AA, Takahashi M, Seward J. Varicella vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines, 4th edn. Philadelphia, PA: WB Saunders 2004; 783-823.
25. Black S, Shinefield H, Ray P, Lewis E, Hansen J, Schwalbe J, et al. Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatr Infect Dis J 1999; 18:1041-6.
26. Wise RP, Salive ME, Braun MM, Mootrey GT, Seward JF, Rider LG, Krause PR. Postlicensure safety surveillance for varicella vaccine. JAMA 2000; 284:1271-9.
27. VARIVAX® Summary of Product Characteristics. http://emc.medicines.org.uk Accessed 2008.
28. Miller E, Waight P, Farrington P, Andrews N, Stowe J, Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001; 84:227-9.
29. Rajantie J, Zeller B, Treutiger I, Rosthoj S. Vaccination associated thrombocytopenic purpura in children. Vaccine 2007; 25:1838-40.
30. Ramet J, Weil-Olivier C, Sedlak W, on behalf of the Confederation of the European Specialists of Paediatrics (CESP)/European Academy of Paediatrics (EAP). Is Europe ready to embrace a policy of universal varicella vaccination? Int J Clin Pract 2005; 59:1326-33.